Evaluation of health related quality of life

BEHAVIORAL2 trials

Sponsors

Fundación para la Investigación del Hospital Clínico de Valencia, Yuzuncu Yil University

Conditions

Heart Failure With Reduced Ejection FractionHemophilia AHemophilia B

Phase 4

Short-term Effects of Dapagliflozin on Peak VO2 in HFrEF

CompletedNCT04197635

Fundación para la Investigación del Hospital Clínico de ValenciaHeart Failure With Reduced Ejection Fraction

Start: 2019-06-01End: 2022-04-19Updated: 2022-04-27

Unknown Phase

Validation and Reliability of the CHO-KLAT in Turkish

Yuzuncu Yil UniversityHemophilia A, Hemophilia B

Start: 2022-06-01End: 2022-12-01Target: 100Updated: 2022-06-30

Related Papers

Short-Term Changes in Peak VO<sub>2</sub> After Initiation of Dapagliflozin in Heart Failure Across Iron Status.

2023-09-0610 citations

Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction—a substudy of the DAPA-VO2 study

Frontiers in Cardiovascular Medicine2023-08-254 citations

Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction.

2023-06-308 citations

Early glomerular filtration rate decline is associated with hemoglobin rise following dapagliflozin initiation in heart failure with reduced ejection fraction.

2023-03-222 citations

Short-term Changes in Hemoglobin and Changes in Functional Status, Quality of Life and Natriuretic Peptides After Initiation of Dapagliflozin in Heart Failure With Reduced Ejection Fraction.

2023-03-045 citations

Short‐term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction ( <scp> DAPA‐VO <sub>2</sub> </scp> ): a randomized clinical trial

European Journal of Heart Failure2022-05-2350 citations